APL 40470/2024

—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Case details: Status
—
Action
Appeal
Category
Main Appeal
Parties: Claimants
Alexion Pharmaceuticals, Inc.
Reps: Wolrad Prinz zu Waldeck Und Pyrmont (Freshfields Bruckhaus Deringer); Christopher Stothers (Freshfields Bruckhaus Deringer); Elena Hennecke (Freshfields Bruckhaus Deringer); Gregor König (Szynka Tilmann von Renesse); Claudia Hertzsch (Szynka Tilmann von Renesse)
Respondents
Samsung Bioepis NL B.V.
Reps: Andrea Ritter (Simmons & Simmons); Peter Meyer (Simmons & Simmons); Scott Parker (Simmons & Simmons); Elsa Glauert (Simmons & Simmons); Fritz Lahrtz (Simmons & Simmons)
Division: Court of Appeal
Judges: Klaus Grabinski · President of the Court of Appeal
Peter Blok · Legally qualified judge and judge-rapporteur
Emmanuel Gougé · Legally qualified judge
Eric Enderlin · Technically qualified judge
Anna Hedberg · Technically qualified judge
Technology: Organic Chemistry
Language: —
First decided: Dec 20, 2024

Decisions

2024-12-20
PI deniedAppeal decisionAppeal RoP220.1
The Court of Appeal dismissed Alexion's appeal against the Hamburg Local Division's refusal to grant provisional measures against Samsung Bioepis regarding patent EP 3167888. The Court addressed the interpretation of patent claims containing linguistic errors and the relevance of prosecution history.
Legal issues:Provisional measuresPatent claim interpretationLinguistic error in patent claimProsecution historyBiosimilar pharmaceutical

Documents